GSK Strengthens its Dermatology Business with Acquisition of Basilea’s Toctino®
By Heather Cartwright
Pharma Deals Review: Vol 2012 Issue 6 (Table of Contents)
Published: 21 Jun-2012
DOI: 10.3833/pdr.v2012.i6.1757 ISSN: 1756-7874
Section: Licensing
Fulltext:
Abstract
In exchange for £146 M (US$226 M) upfront, GlaxoSmithKline’s Stiefel Laboratories has acquired exclusive worldwide rights to Basilea Pharmaceutica’s chronic hand eczema drug Toctino® (oral alitretinoin), which is marketed in 14 countries and reported sales of CHF31 M (US$35 M) in 2011...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
RSS